F-STAR THERAPEUTICS INC (FSTX)
US30315R1077 - Common Stock
F-STAR THERAPEUTICS INC
NASDAQ:FSTX (3/8/2023, 7:00:00 PM)
After market: 7.12 0 (0%)7.12
0 (0%)
Company Profile
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. The firm's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. The company is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.
Company Info
F-STAR THERAPEUTICS INC
Eddeva B920, Babraham Research Campus
CAMBRIDGE MASSACHUSETTS CB22 3AT
P: 441223497400.0
CEO: Eliot Forster
Employees: 84
Website: https://www.f-star.com/
FSTX News
a year ago - invoX PharmainvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
a year ago - Seeking AlphaF-star Therapeutics stock surges as buyer Sino Biopharma gains CFIUS approvalF-star Therapeutics (FSTX) jumped 16% in premarket trading after its sale to Sino Biopharmaceuticals (SBHMY) won approval from the Committee on Foreign Investment in the U.S.CFIUS...
a year ago - F-star Therapeutics, Inc.F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaParties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer...
a year ago - Seeking AlphaCDTX, PTGX and TAST among premarket gainers (NASDAQ:FSTX)ThredUp TDUP +17% on Q4 earnings.Protagonist Therapeutics (PTGX) +20% on positive topline results for Phase 2b FRONTIER 1 clinical trial of Oral IL-23 Receptor Antagonist JNJ-2113...
a year ago - Seeking AlphaF-star Therapeutics stock surges on report sale to Sino Biopharma close to CFIUS OkF-star Therapeutics (FSTX) jumped 15% in premarket trading on a report that its sale to Sino Biopharmaceuticals (SBHMY) is set to gain approval from the Committee on Foreign Investment...
FSTX Twits
Here you can normally see the latest stock twits on FSTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
